{
  "docId": "019dd923-622c-750b-8b98-17b017c6aac8",
  "docSlug": "384ff8288d23",
  "documentTitle": "Acutus Medical Inc. (AFIB)",
  "authorId": "53_Kerrisdale_Capital",
  "authorName": "Kerrisdale Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.77272725,
  "pageNumber": 10,
  "pageCount": 29,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "other",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "This is a text-heavy research note page detailing medical trial outcomes and procedural methodologies.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b98-17b017c6aac8/10",
  "deckHref": "/decks/019dd923-622c-750b-8b98-17b017c6aac8",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b98-17b017c6aac8.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b98-17b017c6aac8#slide-10",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The common denominator between the CONVERGE trial and the PRECEPT trial was that they both were designed to test ablation of AF triggers beyond the pulmonary veins.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-fb8f-761b-afcc-edf6ea6aaccf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.77,
        "x": 0.117,
        "y": 0.46
      },
      "kind": "paragraph",
      "text": "The common denominator between the CONVERGE trial and the PRECEPT trial was that they both were designed to test ablation of AF triggers beyond the pulmonary veins.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76677591-bc18-4740-be1e-fb1225b6891f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.77,
        "x": 0.117,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "For persistent AF, PVI is not nearly as effective. Using a similar measure of effectiveness as in the paroxysmal trials, the landmark STAR AF II trial found that PVI is effective only 40% of the time for patients with persistent AF (50% with AADs).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de5ed5dd-b6bd-4ac2-9911-06d8285acf4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.77,
        "x": 0.117,
        "y": 0.66
      },
      "kind": "source-note",
      "text": "Relevant trials include TOCCASTAR (68% effectiveness), SMART-AF (73% effectiveness), and FIRE AND ICE (65% effectiveness).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ef49940-7ac8-4652-882a-0e44d85e2e9f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}